<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140612018077N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-30</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Cognitive Stimulation with Enjoyable Activities for Elderly with Parkinson’s Disease</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Cognitive Stimulation Interventions Based on Enjoyable Activities with and Without Motivational Feedback on Cognitive, Psychological, and Occupational Functions in the Elderly with Parkinson’s Disease and Cognitive Impairment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/85738</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The type of randomization used in this study is block randomization, which will be performed using the website http://www.randomizer.org by a person independent of the therapist and evaluator. Participants in different groups will have no contact with each other and will receive the interventions on different days. All participants in the three groups will be assessed before the intervention, after the intervention, and at follow-up (six weeks after the end of the intervention), Blinding description: The assessors, data collectors, and the statistician responsible for data analysis will also be blinded to group allocation. The therapists delivering the interventions cannot be blinded due to the nature of the intervention. The principal investigator will not be involved in the intervention delivery or outcome assessment and will only have access to de-identified data.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Parkinson's disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1 will receive cognitive stimulation based on enjoyable occupations combined with motivational feedback. The protocol consists of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each). Each session includes: (1) identifying and selecting meaningful activities (e.g., cooking, painting, gardening) using COPM; (2) embedding cognitive tasks (memory, attention, executive functions) within the activities; (3) providing verbal and visual motivational feedback during activities to enhance engagement and motivation. Intervention 2: The control group will receive routine occupational therapy interventions. These include stretching and strengthening exercises, positioning, postural control training, balance exercises, fine motor skill training, and functional exercises when feasible. The intervention will consist of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each). Intervention 3: Intervention group 2 will receive cognitive stimulation based on enjoyable occupations without motivational feedback. The protocol is identical to group 1, consisting of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each). Activities are selected based on individual preferences and combined with cognitive exercises (memory, attention, executive functions), but no direct motivational feedback (verbal or visual) is provided.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The shared file will include de-identified data from study participants. Specifically, the dataset will contain general demographic information (age, gender), group allocation, and scores related to the primary outcome measures of the study. No personal identifiers such as names, contact details, or national ID numbers will be included. Only this specific part of the data will be available to other researchers upon formal request and after obtaining appropriate approvals. The complete dataset or other sensitive information will not be shared.

When:
One year after publishing the results

To whom:
Researchers working in academic and scientific institutions

Conditions:
Use of the documentation is permitted upon written permission.

Where to obtain:
Maryam Mehdizadeh
Address: Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran,  E-mail: Maryam.mehdizadeh_22@yahoo.com

How to obtain:
Just sending a request by email and mentioning the explanation about the cause of the need for documentation is enough.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Mehdizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran</address>
        <city>Stockholm</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 6121</telephone>
        <email>Maryam.mehdizadeh_22@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Mehdizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 6121</telephone>
        <email>Maryam.mehdizadeh_22@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being at the age of 65 years or older
disease severity of 1–3 on the Hoehn &amp; Yahr scale
impairment of cognitive function, with a score of &lt;24 on the Montreal Cognitive Assessment
idiopathic Parkinson’s disease confirmed by a neurologist</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Comorbid neurological/orthopedic conditions affecting mobility, per physician report
Substance abuse
History of diabetes mellitus</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Parkinson's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1 will receive cognitive stimulation based on enjoyable occupations combined with motivational feedback. The protocol consists of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each). Each session includes: (1) identifying and selecting meaningful activities (e.g., cooking, painting, gardening) using COPM; (2) embedding cognitive tasks (memory, attention, executive functions) within the activities; (3) providing verbal and visual motivational feedback during activities to enhance engagement and motivation.</i_keyword>
      <i_keyword>The control group will receive routine occupational therapy interventions. These include stretching and strengthening exercises, positioning, postural control training, balance exercises, fine motor skill training, and functional exercises when feasible. The intervention will consist of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each).</i_keyword>
      <i_keyword>Intervention group 2 will receive cognitive stimulation based on enjoyable occupations without motivational feedback. The protocol is identical to group 1, consisting of 12 sessions over 6 weeks (2 sessions per week, 60 minutes each). Activities are selected based on individual preferences and combined with cognitive exercises (memory, attention, executive functions), but no direct motivational feedback (verbal or visual) is provided.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Satisfaction of performance. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: The score of satisfaction with performance will be measured using the Canadian Occupational Performance Measure (COPM). This score reflects the participants' level of satisfaction with their performance in daily activities, rated on a 10-point scale, where higher scores indicate greater satisfaction.</prim_outcome>
      <prim_outcome>Performance. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: The performance score will be measured using the Canadian Occupational Performance Measure (COPM). This score reflects the participants' level of performance in daily activities and is recorded on a 10-point scale, where higher scores indicate better performance.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Global cognitive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Montreal Cognitive Assessment (MoCA), a screening tool assessing short-term memory, executive function, attention and concentration, language, and visuospatial skills. Total score ranges from 0 to 30, with higher scores indicating better cognitive performance.</sec_outcome>
      <sec_outcome>Parkinson’s disease-specific cognitive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Parkinson’s Disease Cognitive Rating Scale (PD-CRS), assessing cortical and subcortical cognition. Total score 0–134; lower scores reflect greater impairment.</sec_outcome>
      <sec_outcome>Cognitive performance including attention, processing speed, and executive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: SCOPA-Cog (Scales for Outcomes in Parkinson’s Disease-Cognition), 10 items; total score 0–43, higher scores indicate better performance.</sec_outcome>
      <sec_outcome>Cognitive control and selective attention. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Stroop Test, naming ink color in incongruent conditions; outcomes: response time and error count.</sec_outcome>
      <sec_outcome>Processing speed and cognitive flexibility. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Trail Making Test (TMT), part A (numbers) and part B (alternating numbers and letters). Main outcome: completion time.</sec_outcome>
      <sec_outcome>Executive function and visuospatial memory. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Clock Drawing Test (CDT), drawing a clock with a set time; scored for accuracy and correct placement of hands.</sec_outcome>
      <sec_outcome>Anxiety level. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Hospital Anxiety and Depression Scale (HADS), anxiety subscale with 7 items (scored 0–3). Higher scores = greater anxiety.</sec_outcome>
      <sec_outcome>Depression level. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Hospital Anxiety and Depression Scale (HADS), Depression subscale with 7 items (scored 0–3). Higher scores = greater Depression.</sec_outcome>
      <sec_outcome>Intrinsic motivation in performing activities. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Intrinsic Motivation Inventory (IMI), 45 items across 7 subscales. Total score 45–315.</sec_outcome>
      <sec_outcome>Parkinson’s disease-specific quality of life. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Parkinson’s Disease Questionnaire (PDQ-39), 39 items across 8 domains. Higher scores = poorer quality of life.</sec_outcome>
      <sec_outcome>General quality of life. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: EQ-5D questionnaire, covering 5 domains and a Visual Analogue Scale (VAS).</sec_outcome>
      <sec_outcome>This variable assesses the behavioral, emotional, and cognitive aspects of apathy, including motivation, interest, and goal-directed behavior. Higher scores indicate greater apathy severity. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Apathy Evaluation Scale (AES): An 18-item instrument where items are rated on a 4-point Likert scale. Total scores typically range from 18 to 72.</sec_outcome>
      <sec_outcome>This variable assesses domains of apathy such as intellectual curiosity, emotional response, action initiation, and self-awareness. Higher scores (in the positive range) indicate more severe apathy. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Lille Apathy Rating Scale (LARS): A structured interview consisting of 33 items. Scores are calculated using weighted responses, producing a total score ranging approximately from -36 to +36.</sec_outcome>
      <sec_outcome>This variable evaluates three apathy subdomains: executive apathy, emotional apathy, and initiation apathy. Higher scores on each subscale reflect greater apathy severity in that specific domain. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Dimensional Apathy Scale (DAS): A 24-item scale where items are rated on a 4-point Likert scale. Subscale and total scores are calculated.</sec_outcome>
      <sec_outcome>This performance-based measure assesses functional mobility, balance, and gait speed under a standard condition (single-task) and while simultaneously performing a cognitive task (dual-task). Longer completion times indicate poorer mobility. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Timed Up and Go Test (TUG): A performance-based measure that times the completion of a standardized movement sequence. The dual-task version adds a concurrent cognitive task.</sec_outcome>
      <sec_outcome>This variable assesses fear of movement, injury, and re-injury during physical activity. Higher scores indicate greater fear of movement and avoidance behavior. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Tampa Scale of Kinesiophobia (TSK): A 17-item scale where items are rated on a 4-point Likert scale. Total scores range from 17 to 68.</sec_outcome>
      <sec_outcome>This variable assesses the flow experience, including absorption, fluency of performance, and perceived control during task performance. Higher scores indicate greater flow experience and task engagement. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Flow Short Scale (FSS): A 13-item instrument where items are rated using Likert-type scales.</sec_outcome>
      <sec_outcome>This variable assesses flow during occupational or work-related activities, including concentration, intrinsic motivation, sense of control, and time transformation. Higher scores indicate a stronger flow experience. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Flow State Scale for Occupational Tasks: A 14-item scale where items are rated on Likert scales and summed to produce a total score.</sec_outcome>
      <sec_outcome>This variable assesses engagement, enjoyment, perceived competence, and immersion during rehabilitation exercises and therapy sessions. Higher scores indicate greater engagement and an optimal experiential state. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Flow State Scale for Rehabilitation Tasks (FSSOT): A 14-item scale adapted to measure flow during rehabilitation activities.</sec_outcome>
      <sec_outcome>This variable assesses fear-related beliefs, avoidance behaviors, and emotional responses related to movement or pain. Higher scores indicate stronger fear-avoidance beliefs and behavioral avoidance patterns. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Fear-Avoidance Components Scale (FACS): An instrument containing 16-20 items that are scored using Likert-type ratings.</sec_outcome>
      <sec_outcome>This variable assesses the level of concern about falling during daily physical and social activities. Higher scores indicate a greater fear of falling and lower balance confidence. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Falls Efficacy Scale–International (FES-I): A 16-item scale where each item is rated on a 4-point scale. Total scores range from 16 to 64.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-08-18</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>ran University of Medical Sciences (IUMS), next to Milad Tower, Hemmat Expressway, Postal Code: 1449614535 Stockholm Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
